RxDoctor Payments Data

Tiana Nygaard

Medical · Pensacola, FLNPI 1477828614

Payments from drug & device makers

$301in general payments, 2019–2025

Across 8 payments — averaging $37.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanara Medtech Inc.$102
  • Myriad Genetic Laboratories, Inc.$97
  • Boston Scientific$23
  • Abbott$19
  • Sunovion Pharmaceuticals Inc.$15
  • Otsuka America Pharmaceutical, Inc.$15
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$301 in reported general payments places this provider in the 35th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$204,767
Medicare patients
131
Services billed
1,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$42,182
XareltoRivaroxaban48$24,928
CreonLipase/Protease/Amylase13$18,854
EntrestoSacubitril/Valsartan25$17,582
GemtesaVibegron15$9,926
NamzaricMemantine Hcl/Donepezil Hcl13$7,621
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,536
FarxigaDapagliflozin Propanediol13$7,319
Rivastigmine29$6,794
Memantine Hcl69$4,321
Quetiapine Fumarate170$3,913
Rosuvastatin Calcium65$3,064
Potassium Chloride119$2,387
Pantoprazole Sodium125$2,190
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst55$2,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Namzaric$14$26,47526 claims
AstraZenecaBreztri Aerosphere, Farxiga$15$14,85425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,031 medical providers in Florida.

Other medical in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →